Hanmi Pharm's obesity treatment Eppe wins domestic approval
The Ministry of Food and Drug Safety on Thursday approved Hanmi Pharmaceutical's Eppe, Korea's first domestically developed glucagon-like peptide-1 (GLP-1)-based obesity treatment. Eppe is the 45th novel drug developed in Korea and the country's first domestically developed GLP-1-based obesity drug. It has been approved in five doses: 2, 4, 6, 8 and 10 milligrams. According to the ministry, the…
Read original article on Korea Times News →Related news
-
UN calls US plans to livestream execution 'abhorrent'
-
US stocks rise toward finish of record-breaking week
-
US imposes sanctions on International Criminal Court, hours after former judge wins Nobel
-
How the US plan to livestream an execution compares with global practice
-
Outrage over US military plan to livestream firing squad execution
-
'Enemies in the Outfield' blends baseball into dating show
-
Comedy takes root in Korea's Russian-speaking community
-
Trump says US to get diesel from Russia, relaxing pressure on Moscow to ease prices before midterms